Covered recipient · General Payments record
MITCHELL SHIFFMAN
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$105,797.15
155 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,990.00 | 11 |
| Travel and Lodging | $19,754.34 | 50 |
| Consulting Fee | $15,597.50 | 5 |
| Honoraria | $11,980.00 | 8 |
| Compensation for serving as faculty or as a speaker for a medical education program | $10,540.00 | 3 |
| Food and Beverage | $6,935.31 | 78 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $34,499.58 | 62 |
| Madrigal Pharmaceuticals | $16,590.18 | 17 |
| Intercept Pharmaceuticals, Inc. | $14,864.27 | 12 |
| Ipsen Biopharmaceuticals, Inc | $11,673.28 | 9 |
| Intra-Sana Laboratories | $8,496.43 | 8 |
| Mirum Pharmaceuticals, Inc. | $5,976.48 | 10 |
| Novo Nordisk Inc | $5,155.43 | 3 |
| Genentech USA, Inc. | $4,120.29 | 5 |
| Ipsen Bioscience Inc. | $1,810.71 | 6 |
| HISTOSONICS,INC. | $711.25 | 3 |
| FUJIFILM Healthcare Americas Corporation | $393.30 | 4 |
| AstraZeneca Pharmaceuticals LP | $326.49 | 4 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $321.21 | 3 |
| Exact Sciences Corporation | $263.87 | 3 |
| Exelixis Inc. | $136.80 | 1 |
| Boston Scientific Corporation | $136.30 | 1 |
| Alnylam Pharmaceuticals Inc. | $122.58 | 1 |
| Genentech, Inc. | $91.74 | 1 |
| Echosens North America, Inc. | $70.19 | 1 |
| ABBVIE INC. | $36.77 | 1 |
Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MITCHELL SHIFFMAN
NPI 1497847461 · CMS profile ID 294197
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
NEWPORT NEWS, VA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1497847461?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MITCHELL SHIFFMAN, NPI 1497847461, CMS profile ID 294197. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497847461?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MITCHELL SHIFFMAN, NPI 1497847461, CMS profile ID 294197. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497847461?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MITCHELL SHIFFMAN, NPI 1497847461, CMS profile ID 294197, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1497847461?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
155 matching records · $105,797.15 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 155.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $15.11 | 05/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133777431 | CMS |
| Gilead Sciences, Inc. | $20.91 | 05/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133777433 | CMS |
| Gilead Sciences, Inc. | $25.96 | 05/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864576 | CMS |
| Gilead Sciences, Inc. | $118.17 | 05/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864578 | CMS |
| Gilead Sciences, Inc. | $720.75 | 05/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864580 | CMS |
| Gilead Sciences, Inc. | $724.80 | 05/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864582 | CMS |
| Gilead Sciences, Inc. | $846.66 | 05/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864584 | CMS |
| Gilead Sciences, Inc. | $6.88 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133777423 | CMS |
| Gilead Sciences, Inc. | $58.78 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133777425 | CMS |
| Gilead Sciences, Inc. | $138.00 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133777427 | CMS |
| Gilead Sciences, Inc. | $65.92 | 05/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864572 | CMS |
| Gilead Sciences, Inc. | $75.47 | 05/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864574 | CMS |
| AstraZeneca Pharmaceuticals LP | $28.57 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105783536 | CMS |
| Novo Nordisk Inc | $2,712.50 | 05/06/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1096931637 | CMS |
| Exelixis Inc. | $136.80 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138562368 | CMS |
| FUJIFILM Healthcare Americas Corporation | $86.56 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146124966 | CMS |
| Intercept Pharmaceuticals, Inc. | $114.50 | 04/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113639593 | CMS |
| Intercept Pharmaceuticals, Inc. | $1,267.50 | 04/16/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113639595 | CMS |
| Intercept Pharmaceuticals, Inc. | $4,960.00 | 04/16/2024 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113639597 | CMS |
| Intra-Sana Laboratories | $750.00 | 04/16/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138620030 | CMS |
| Gilead Sciences, Inc. | $4,930.00 | 04/15/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133605272 | CMS |
| Gilead Sciences, Inc. | $86.55 | 04/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133777421 | CMS |
| Gilead Sciences, Inc. | $96.61 | 04/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864570 | CMS |
| Gilead Sciences, Inc. | $67.98 | 04/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133777419 | CMS |
| Gilead Sciences, Inc. | $42.17 | 04/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133777417 | CMS |
| Gilead Sciences, Inc. | $23.86 | 04/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864566 | CMS |
| Gilead Sciences, Inc. | $26.00 | 04/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864568 | CMS |
| Ipsen Biopharmaceuticals, Inc | $2,523.00 | 04/04/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091967009 | CMS |
| Gilead Sciences, Inc. | $110.71 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133777415 | CMS |
| Intercept Pharmaceuticals, Inc. | $1,240.00 | 03/25/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113639591 | CMS |
| Intra-Sana Laboratories | $1,500.00 | 03/21/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138620028 | CMS |
| Alnylam Pharmaceuticals Inc. | $122.58 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125854717 | CMS |
| FUJIFILM Healthcare Americas Corporation | $99.64 | 03/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146124946 | CMS |
| Gilead Sciences, Inc. | $49.99 | 03/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133777413 | CMS |
| Gilead Sciences, Inc. | $298.50 | 03/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864560 | CMS |
| Gilead Sciences, Inc. | $350.00 | 03/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864562 | CMS |
| Gilead Sciences, Inc. | $520.70 | 03/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864564 | CMS |
| Intra-Sana Laboratories | $1,500.00 | 02/27/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138620026 | CMS |
| Novo Nordisk Inc | $2,325.00 | 02/22/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097693981 | CMS |
| Intra-Sana Laboratories | $120.10 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138620024 | CMS |
| Genentech USA, Inc. | $207.18 | 02/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133074051 | CMS |
| Genentech USA, Inc. | $152.07 | 02/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133074055 | CMS |
| Genentech USA, Inc. | $138.64 | 02/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133074059 | CMS |
| Genentech USA, Inc. | $2,939.52 | 02/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133074063 | CMS |
| Genentech USA, Inc. | $682.88 | 02/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133074067 | CMS |
| Gilead Sciences, Inc. | $3,240.00 | 02/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133605280 | CMS |
| HISTOSONICS,INC. | $142.30 | 02/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154803275 | CMS |
| Intra-Sana Laboratories | $1,500.00 | 01/25/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138620022 | CMS |
| Exact Sciences Corporation | $92.07 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114895159 | CMS |
| Exact Sciences Corporation | $98.66 | 01/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114895162 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,198,804.14 | 205 |
| PY2024 | Principal investigator | $575,196.17 | 103 |
| PY2023 | Principal investigator | $184,035.14 | 23 |
| PY2022 | Principal investigator | $209,840.21 | 32 |
| PY2021 | Principal investigator | $417,616.19 | 215 |
| PY2020 | Principal investigator | $424,274.57 | 73 |
| PY2019 | Recipient | $1,052.00 | 1 |
| PY2019 | Principal investigator | $1,008,010.51 | 123 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
205 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,337.85 | 12/19/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254307 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,600.00 | 12/16/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206440 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,739.00 | 12/16/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206448 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,075.00 | 12/11/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546917 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $691.40 | 12/11/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546919 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $325.30 | 12/11/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546921 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,308.20 | 12/11/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546923 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $421.20 | 12/11/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546925 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,655.45 | 12/11/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546927 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,965.95 | 12/11/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546929 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,250.00 | 12/11/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546931 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,006.00 | 12/11/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546933 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $998.00 | 12/11/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546935 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,000.00 | 12/11/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546937 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,588.25 | 12/11/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253834 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,511.04 | 12/11/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253838 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,500.00 | 12/10/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223289518 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,471.00 | 12/04/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546915 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,939.38 | 12/04/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253316 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $300.00 | 12/04/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253340 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $600.00 | 12/04/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253344 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,570.14 | 12/02/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253204 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $45,556.47 | 12/01/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC D | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223288977 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,295.06 | 11/25/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252866 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,000.00 | 11/25/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252875 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,000.00 | 11/25/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252878 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,000.00 | 11/25/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252882 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $85.05 | 11/17/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248252661 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $707.50 | 11/17/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248252666 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 11/14/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) | No dispute reported | 06/30/2026 | 1184307045 |
| Principal investigator 1 | Ipsen Pharma SAS | $800.00 | 11/14/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) | No dispute reported | 06/30/2026 | 1184307047 |
| Principal investigator 1 | Gilead Sciences, Inc. | $4,800.00 | 11/12/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206432 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,939.38 | 11/07/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252400 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,885.82 | 11/07/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252404 |
| Principal investigator 1 | Gilead Sciences, Inc. | $500.00 | 10/29/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203948 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,000.00 | 10/29/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203955 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,843.04 | 10/24/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203965 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $114.75 | 10/17/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC D | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223287119 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,118.56 | 10/09/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251412 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $116.00 | 10/03/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546911 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $116.00 | 10/03/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546913 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,118.56 | 10/03/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250940 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $14,000.00 | 10/03/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250952 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,128.87 | 10/03/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248251030 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,600.00 | 09/29/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248250763 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 09/25/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211581826 |
| Principal investigator 1 | Genentech, Inc. | $2,000.00 | 09/25/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211581830 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 09/25/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211581834 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 09/25/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211581838 |
| Principal investigator 1 | Genentech, Inc. | $1,950.00 | 09/25/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211581846 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 09/25/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211581853 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,230.00 | 09/23/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206425 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,588.25 | 09/23/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250530 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,588.25 | 09/18/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250111 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,200.00 | 09/18/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250115 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $49,924.38 | 09/18/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250119 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $300.00 | 09/18/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250123 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $100.00 | 09/18/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250135 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,993.71 | 09/16/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206418 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,000.00 | 09/12/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546907 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $600.00 | 09/12/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546909 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,118.56 | 09/12/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249878 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,597.63 | 09/05/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249724 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,118.56 | 09/04/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249386 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,469.69 | 08/26/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249062 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $3,008.00 | 08/21/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546905 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,334.45 | 08/21/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248836 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,353.00 | 08/19/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206412 |
| Principal investigator 1 | Gilead Sciences, Inc. | $10,820.00 | 08/12/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206403 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,237.12 | 08/07/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248060 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 08/01/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223283507 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,750.00 | 08/01/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223283509 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,627.64 | 07/31/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247686 |
| Principal investigator 1 | Genentech, Inc. | $800.00 | 07/22/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211581843 |
| Principal investigator 1 | Genentech, Inc. | $4,000.00 | 07/22/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211581849 |
| Principal investigator 1 | Gilead Sciences, Inc. | $5,637.00 | 07/22/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206394 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $3,008.00 | 07/22/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546903 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $12,927.60 | 07/18/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248247265 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,417.34 | 07/18/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223282822 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,069.20 | 07/16/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203931 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,474.95 | 07/16/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203940 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $3,008.00 | 07/10/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546901 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,570.14 | 07/10/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248246757 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,530.00 | 07/08/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206369 |
| Principal investigator 1 | Gilead Sciences, Inc. | $288.00 | 07/08/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206376 |
| Principal investigator 1 | Gilead Sciences, Inc. | $170.10 | 07/08/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206386 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,097.33 | 07/04/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246591 |
| Principal investigator 1 | Gilead Sciences, Inc. | $78.30 | 07/02/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203925 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,337.85 | 06/24/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246072 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,885.82 | 06/24/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246077 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,771.64 | 06/24/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246089 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $21,952.36 | 06/20/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223281692 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $600.00 | 06/20/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223281694 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,500.00 | 06/19/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546895 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,250.00 | 06/19/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546897 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $998.00 | 06/19/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546899 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,118.56 | 06/19/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245811 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,469.69 | 06/19/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245819 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $250.00 | 06/19/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245827 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,578.23 | 06/19/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245830 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $28.35 | 06/19/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248245842 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,808.50 | 06/19/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248245847 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $500.00 | 06/19/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248245850 |
| Principal investigator 1 | Gilead Sciences, Inc. | $5,689.00 | 06/17/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206361 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,949.92 | 06/16/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245656 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,118.56 | 06/12/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245333 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,255.28 | 06/12/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245341 |
| Principal investigator 1 | Gilead Sciences, Inc. | $300.00 | 06/10/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206341 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,310.00 | 06/10/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206353 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,500.00 | 06/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) | No dispute reported | 06/30/2026 | 1184307041 |
| Principal investigator 1 | Ipsen Pharma SAS | $13,500.00 | 06/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) | No dispute reported | 06/30/2026 | 1184307043 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,246.08 | 06/05/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244908 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $200.00 | 06/05/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244912 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,000.00 | 06/04/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203888 |
| Principal investigator 1 | Gilead Sciences, Inc. | $500.00 | 06/04/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203896 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,750.00 | 06/04/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223280658 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 06/04/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223280660 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 06/04/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223280662 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,357.44 | 06/04/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223280664 |
| Principal investigator 1 | Gilead Sciences, Inc. | $7,750.00 | 06/03/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206318 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,140.00 | 06/03/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206325 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,020.00 | 06/03/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206333 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $22,996.27 | 06/02/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223280564 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,227.15 | 05/29/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248244769 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,116.95 | 05/29/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248244773 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,373.84 | 05/28/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244647 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,400.00 | 05/28/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223280434 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,377.00 | 05/22/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546893 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,496.32 | 05/22/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244248 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,500.00 | 05/22/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244252 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,750.00 | 05/22/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244255 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,400.00 | 05/22/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244259 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,000.00 | 05/22/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244263 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,147.85 | 05/21/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223280012 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $400.00 | 05/21/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223280014 |
| Principal investigator 1 | Gilead Sciences, Inc. | $8,653.00 | 05/20/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206301 |
| Principal investigator 1 | Gilead Sciences, Inc. | $4,110.00 | 05/20/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206310 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,933.88 | 05/16/2025 | Non-covered Recipient Entity Sc Liver Research Consortium | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184307593 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,005.40 | 05/15/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243695 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,633.04 | 05/15/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243700 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,500.00 | 05/15/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243704 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,750.00 | 05/15/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243707 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,130.72 | 05/15/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243715 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,000.00 | 05/15/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243719 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,500.00 | 05/08/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546891 |
| Principal investigator 1 | Gilead Sciences, Inc. | $5,132.16 | 05/07/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203904 |
| Principal investigator 1 | Ipsen Pharma SAS | $11,866.40 | 05/07/2025 | Non-covered Recipient Entity Sc Liver Research Consortium | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184307581 |
| Principal investigator 1 | Ipsen Pharma SAS | $12,948.00 | 05/07/2025 | Non-covered Recipient Entity Sc Liver Research Consortium | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184307583 |
| Principal investigator 1 | Ipsen Pharma SAS | $12,948.00 | 05/07/2025 | Non-covered Recipient Entity Sc Liver Research Consortium | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184307585 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $700.00 | 05/07/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223279100 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,032.77 | 05/07/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223279102 |
| Principal investigator 1 | Genentech, Inc. | $1,600.00 | 05/06/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211581803 |
| Principal investigator 1 | Genentech, Inc. | $65.00 | 05/06/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211581807 |
| Principal investigator 1 | Genentech, Inc. | $8,000.00 | 05/06/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211581811 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $9,000.00 | 05/02/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546883 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,736.00 | 05/02/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546885 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $12,500.00 | 05/02/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546887 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $13,000.00 | 05/02/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546889 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,377.00 | 04/28/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546881 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,885.82 | 04/28/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242794 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $250.00 | 04/26/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242647 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,843.04 | 04/25/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203918 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,631.19 | 04/24/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248242619 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $438.00 | 04/23/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242564 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,200.00 | 04/23/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242568 |
| Principal investigator 1 | Gilead Sciences, Inc. | $39,295.00 | 04/22/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206293 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,377.00 | 04/15/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546879 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,895.98 | 04/11/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242319 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,992.64 | 04/08/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248241774 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,097.33 | 04/08/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248241777 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,800.00 | 03/13/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240883 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $21,982.16 | 03/13/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240886 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,985.75 | 03/12/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223276337 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,882.92 | 03/06/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240265 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,296.65 | 03/06/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240269 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,471.00 | 03/04/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546877 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,050.00 | 02/14/2025 | Non-covered Recipient Entity BON SECOURS-RICHMOND COMMUNITY HOSPITAL INCORPORATED | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248239770 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $40,141.42 | 02/06/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239092 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,496.32 | 02/06/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239096 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $15,765.84 | 02/06/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239100 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,471.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546853 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,000.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546855 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,736.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546857 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $12,500.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546859 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $17,000.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546861 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,598.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546863 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $333.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546865 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $222.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546867 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $359.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546869 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $7,000.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546871 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,250.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546873 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,303.00 | 02/05/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546875 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $23,782.16 | 01/30/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238863 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $58.00 | 01/29/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546849 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,400.00 | 01/29/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546851 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,471.00 | 01/21/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546847 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $240,347.58 | 01/16/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238503 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,000.00 | 01/15/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208537 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,000.00 | 01/15/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208546 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,750.00 | 01/15/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208553 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,000.00 | 01/15/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208560 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $7,553.00 | 01/07/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546843 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $447.00 | 01/07/2025 | Non-covered Recipient Entity Bon Secours Mercy Health, Inc | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546845 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,407.04 | 01/03/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248237873 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,032.85 | 01/03/2025 | Non-covered Recipient Entity BON SECOURS MERCY HEALTH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238008 |